{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:12:14Z","timestamp":1788491534649,"version":"build-2803163510"},"reference-count":146,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"\n OBJECTIVE<\/jats:title>\n Osteoporosis represents the most common metabolic disease of the bone, with an estimated 10% of adults aged 50 years or older affected in the United States. This patient population is at increased risk for spine fracture and instrumentation-related complications after spine surgery. Surgeon knowledge of the available treatments for patients with low bone mineral density (BMD) and how they impact biology of fusion may help mitigate negative effects in the postoperative period. Recombinant parathyroid hormone, which is sold under the name teriparatide, is the most extensively studied bone-protecting agent in humans. Additionally, the success of the monoclonal antibody denosumab has led to further clinical investigations of human patients undergoing spine surgery. Another monoclonal antibody, romosozumab, was recently approved by the US FDA for human use in patients with osteoporosis. Although studies of romosozumab in patients undergoing spine surgery have not been conducted, this is a promising potential therapeutic agent based on its early success in preclinical and clinical trials. Here, the authors aimed to review the mechanisms of action and evidence of use of antiresorptive and anabolic agents in patients with osteoporosis undergoing spine surgery.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n In accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, a systematic review was conducted to explore the antiresorptive and anabolic agents used in the perioperative period in patients with osteoporosis undergoing spinal surgery. The search was performed by using the PubMed, Embase, and Cochrane Library databases. Titles and abstracts were screened and subsequently selected for full review.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n The initial search returned 330 articles. Of these articles, 23 final articles were included and reviewed. Many of these articles reported that use of adjuvant agents in the perioperative period improved radiographic evidence of bony fusion and bone fusion rates. These agents tended to improve BMD postoperatively.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Although antiosteoporosis agents are effective to varying degrees as treatments of patients with low BMD, teriparatide and bisphosphonates have been the most extensively studied with respect to spinal instrumentation. The advent of newer agents represents an area for further exploration, especially due to the current paucity of controlled investigations. It is imperative for spine surgeons to understand the mechanisms of action of these drugs and their effects on biology of fusion.<\/jats:p>\n <\/jats:sec>","DOI":"10.3171\/2021.3.focus201049","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T03:25:58Z","timestamp":1622517958000},"page":"E13","source":"Crossref","is-referenced-by-count":20,"title":["Antiresorptive and anabolic medications used in the perioperative period of patients with osteoporosis undergoing spine surgery: their impact on the biology of fusion and systematic review of the literature"],"prefix":"10.3171","volume":"50","author":[{"given":"Jean-Paul","family":"Bryant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto J.","family":"Perez-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Shelby","family":"Burks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"4","key":"r1","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00198-016-3865-3","article-title":"The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA","volume":"28","author":"Wright NC","year":"2017","unstructured":"Wright NC, Saag KG, Dawson-Hughes B, The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int. 2017;28(4):1225\u20131232.10.1007\/s00198-016-3865-327966104"},{"key":"r2","article-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","author":"Office of the Surgeon General","year":"2004","unstructured":"Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General; 2004."},{"issue":"9","key":"r3","series-title":"Geriatrics","first-page":"20","article-title":"Osteoporosis in older men: discovering when and how to treat it","volume":"54","author":"Siddiqui NA","year":"1999","unstructured":"Siddiqui NA, Shetty KR, Duthie EH Jr. Osteoporosis in older men: discovering when and how to treat it. Geriatrics. 1999;54(9):20\u201322, 27\u201328, 30 passim.10494225"},{"issue":"4","key":"r4","series-title":"Clin Spine Surg","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/BSD.0000000000000376","article-title":"Medical management of osteoporosis for elective spine surgery","volume":"29","author":"Hassanzadeh H","year":"2016","unstructured":"Hassanzadeh H, Puvanesarajah V, Dalkin AC. Medical management of osteoporosis for elective spine surgery. Clin Spine Surg. 2016;29(4):134\u2013140.10.1097\/BSD.000000000000037627100945"},{"issue":"7","key":"r5","series-title":"Am Fam Physician","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion JM","year":"2003","unstructured":"Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician. 2003;67(7):1521\u20131526.12722852"},{"issue":"43","key":"r6","series-title":"Medicine (Baltimore)","doi-asserted-by":"publisher","first-page":"e8294","DOI":"10.1097\/MD.0000000000008294","article-title":"Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: a cross-sectional study in Gansu province, Northwestern of China","volume":"96","author":"Tian L","year":"2017","unstructured":"Tian L, Yang R, Wei L, Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: a cross-sectional study in Gansu province, Northwestern of China. Medicine (Baltimore). 2017;96(43):e8294.10.1097\/MD.0000000000008294"},{"issue":"1","key":"r7","series-title":"Endocrinol Metab Clin North Am","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ecl.2013.09.004","article-title":"Osteoporosis-associated fracture and diabetes","volume":"43","author":"Kurra S","year":"2014","unstructured":"Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin North Am. 2014;43(1):233\u2013243.10.1016\/j.ecl.2013.09.00424582100"},{"issue":"19)(suppl","key":"r8","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1097\/01.brs.0000236893.65878.39","article-title":"Instrumentation-related complications of multilevel fusions for adult spinal deformity patients over age 65: surgical considerations and treatment options in patients with poor bone quality","volume":"31","author":"DeWald CJ","year":"2006","unstructured":"DeWald CJ, Stanley T. Instrumentation-related complications of multilevel fusions for adult spinal deformity patients over age 65: surgical considerations and treatment options in patients with poor bone quality. Spine (Phila Pa 1976). 2006;31(19)(suppl):S144\u2013S151.10.1097\/01.brs.0000236893.65878.39"},{"issue":"4","key":"r9","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3171\/2010.4.SPINE09764","article-title":"Evaluation of pullout strength and failure mechanism of posterior instrumentation in normal and osteopenic thoracic vertebrae","volume":"13","author":"Paxinos O","year":"2010","unstructured":"Paxinos O, Tsitsopoulos PP, Zindrick MR, Evaluation of pullout strength and failure mechanism of posterior instrumentation in normal and osteopenic thoracic vertebrae. J Neurosurg Spine. 2010;13(4):469\u2013476.2088714410.3171\/2010.4.SPINE09764"},{"issue":"9","key":"r10","series-title":"Bone Joint Res","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1302\/2046-3758.59.2000580","article-title":"Pull-out strength of cemented solid versus fenestrated pedicle screws in osteoporotic vertebrae","volume":"5","author":"Leichtle CI","year":"2016","unstructured":"Leichtle CI, Lorenz A, Rothstock S, Pull-out strength of cemented solid versus fenestrated pedicle screws in osteoporotic vertebrae. Bone Joint Res. 2016;5(9):419\u2013426.10.1302\/2046-3758.59.200058027678328"},{"issue":"15","key":"r11","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1097\/00007632-199311000-00016","article-title":"Stability of transpedicle screwing for the osteoporotic spine. An in vitro study of the mechanical stability","volume":"18","author":"Okuyama K","year":"1993","unstructured":"Okuyama K, Sato K, Abe E, Stability of transpedicle screwing for the osteoporotic spine. An in vitro study of the mechanical stability. Spine (Phila Pa 1976). 1993;18(15):2240\u20132245.10.1097\/00007632-199311000-00016"},{"issue":"21","key":"r12","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1097\/00007632-199411000-00008","article-title":"Effects of bone mineral density on pedicle screw fixation","volume":"19","author":"Halvorson TL","year":"1994","unstructured":"Halvorson TL, Kelley LA, Thomas KA, Effects of bone mineral density on pedicle screw fixation. Spine (Phila Pa 1976). 1994;19(21):2415\u20132420.10.1097\/00007632-199411000-00008"},{"issue":"11","key":"r13","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/00007632-199111000-00015","article-title":"An experimental study on transpedicular screw fixation in relation to osteoporosis of the lumbar spine","volume":"16","author":"Soshi S","year":"1991","unstructured":"Soshi S, Shiba R, Kondo H, Murota K. An experimental study on transpedicular screw fixation in relation to osteoporosis of the lumbar spine. Spine (Phila Pa 1976). 1991;16(11):1335\u20131341.10.1097\/00007632-199111000-00015"},{"issue":"6","key":"r14","series-title":"J Orthop Sci","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jos.2018.06.009","article-title":"Effect of osteoporosis on the clinical and radiological outcomes following one-level posterior lumbar interbody fusion","volume":"23","author":"Cho JH","year":"2018","unstructured":"Cho JH, Hwang CJ, Kim H, Effect of osteoporosis on the clinical and radiological outcomes following one-level posterior lumbar interbody fusion. J Orthop Sci. 2018;23(6):870\u2013877.10.1016\/j.jos.2018.06.00930431006"},{"issue":"17","key":"r15","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1097\/BRS.0b013e31824e4888","article-title":"Incidence, risk factors, and natural course of proximal junctional kyphosis: surgical outcomes review of adult idiopathic scoliosis. Minimum 5 years of follow-up","volume":"37","author":"Yagi M","year":"2012","unstructured":"Yagi M, King AB, Boachie-Adjei O. Incidence, risk factors, and natural course of proximal junctional kyphosis: surgical outcomes review of adult idiopathic scoliosis. Minimum 5 years of follow-up. Spine (Phila Pa 1976). 2012;37(17):1479\u20131489.10.1097\/BRS.0b013e31824e4888"},{"key":"r16","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.wneu.2016.11.135","article-title":"Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients","volume":"100","author":"Chaudhary N","year":"2017","unstructured":"Chaudhary N, Lee JS, Wu JY, Tharin S. Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients. World Neurosurg. 2017;100:551\u2013556.2792375810.1016\/j.wneu.2016.11.135"},{"issue":"8","key":"r17","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"E487","DOI":"10.1097\/BRS.0b013e31828826dd","article-title":"Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective","volume":"38","author":"Ohtori S","year":"2013","unstructured":"Ohtori S, Inoue G, Orita S, Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38(8):E487\u2013E492.10.1097\/BRS.0b013e31828826dd"},{"issue":"3","key":"r18","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3171\/2014.5.SPINE13656","article-title":"Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis","volume":"21","author":"Inoue G","year":"2014","unstructured":"Inoue G, Ueno M, Nakazawa T, Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine. 2014;21(3):425\u2013431.10.3171\/2014.5.SPINE1365624905394"},{"issue":"4","key":"r19","series-title":"Asian Spine J","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4184\/asj.2015.9.4.573","article-title":"More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery","volume":"9","author":"Ohtori S","year":"2015","unstructured":"Ohtori S, Orita S, Yamauchi K, More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. Asian Spine J. 2015;9(4):573\u2013580.2624071710.4184\/asj.2015.9.4.573"},{"issue":"9886","key":"r20","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai JN","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H, Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50\u201356.10.1016\/S0140-6736(13)60856-9"},{"issue":"1","key":"r21","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.spinee.2015.08.061","article-title":"Effect of a selective estrogen receptor modulator on bone formation in osteoporotic spine fusion using an ovariectomized rat model","volume":"16","author":"Park SB","year":"2016","unstructured":"Park SB, Kim CH, Hong M, Effect of a selective estrogen receptor modulator on bone formation in osteoporotic spine fusion using an ovariectomized rat model. Spine J. 2016;16(1):72\u201381.10.1016\/j.spinee.2015.08.061"},{"issue":"9","key":"r22","series-title":"J Orthop Res","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/jor.22763","article-title":"Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis","volume":"33","author":"Yasen M","year":"2015","unstructured":"Yasen M, Li X, Jiang L, Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis. J Orthop Res. 2015;33(9):1297\u20131304.10.1002\/jor.22763"},{"issue":"18","key":"r23","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1097\/BRS.0b013e3181f49c47","article-title":"The influence of alendronate on spine fusion in an osteoporotic animal model","volume":"36","author":"Nakao S","year":"2011","unstructured":"Nakao S, Minamide A, Kawakami M, The influence of alendronate on spine fusion in an osteoporotic animal model. Spine (Phila Pa 1976). 2011;36(18):1446\u20131452.10.1097\/BRS.0b013e3181f49c47"},{"issue":"3","key":"r24","series-title":"J Orthop Res","first-page":"937","article-title":"Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia","volume":"36","author":"Yishake M","year":"2018","unstructured":"Yishake M, Yasen M, Jiang L, Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia. J Orthop Res. 2018;36(3):937\u2013944."},{"issue":"4","key":"r25","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3171\/2010.11.SPINE10245","article-title":"Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial","volume":"14","author":"Nagahama K","year":"2011","unstructured":"Nagahama K, Kanayama M, Togawa D, Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. J Neurosurg Spine. 2011;14(4):500\u2013507.2127554910.3171\/2010.11.SPINE10245"},{"issue":"4","key":"r26","series-title":"Clin Orthop Surg","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4055\/cios.2013.5.4.292","article-title":"The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion","volume":"5","author":"Park YS","year":"2013","unstructured":"Park YS, Kim HS, Baek SW, The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. Clin Orthop Surg. 2013;5(4):292\u2013297.10.4055\/cios.2013.5.4.29224340149"},{"issue":"1","key":"r27","series-title":"J Surg Res","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jss.2014.05.034","article-title":"Zoledronic acid infusion for lumbar interbody fusion in osteoporosis","volume":"192","author":"Tu CW","year":"2014","unstructured":"Tu CW, Huang KF, Hsu HT, Zoledronic acid infusion for lumbar interbody fusion in osteoporosis. J Surg Res. 2014;192(1):112\u2013116.2494854510.1016\/j.jss.2014.05.034"},{"issue":"4","key":"r28","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00198-015-3398-1","article-title":"Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion","volume":"27","author":"Chen F","year":"2016","unstructured":"Chen F, Dai Z, Kang Y, Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion. Osteoporos Int. 2016;27(4):1469\u20131476.10.1007\/s00198-015-3398-1"},{"issue":"8","key":"r29","series-title":"Eur Spine J","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00586-017-4959-0","article-title":"Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis","volume":"26","author":"Seki S","year":"2017","unstructured":"Seki S, Hirano N, Kawaguchi Y, Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J. 2017;26(8):2121\u20132127.10.1007\/s00586-017-4959-028116510"},{"issue":"1","key":"r30","series-title":"BMC Musculoskelet Disord","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12891-020-03452-6","article-title":"Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study","volume":"21","author":"Kawabata A","year":"2020","unstructured":"Kawabata A, Yoshii T, Hirai T, Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study. BMC Musculoskelet Disord. 2020;21(1):420.10.1186\/s12891-020-03452-632611386"},{"issue":"13","key":"r31","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/BRS.0000000000003426","article-title":"Weekly teriparatide versus bisphosphonate for bone union during 6 months after multi-level lumbar interbody fusion for osteoporotic patients: a multicenter, prospective, randomized study","volume":"45","author":"Oba H","year":"2020","unstructured":"Oba H, Takahashi J, Yokomichi H, Weekly teriparatide versus bisphosphonate for bone union during 6 months after multi-level lumbar interbody fusion for osteoporotic patients: a multicenter, prospective, randomized study. Spine (Phila Pa 1976). 2020;45(13):863\u2013871.10.1097\/BRS.0000000000003426"},{"issue":"11","key":"r32","series-title":"Eur Spine J","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s00586-017-5286-1","article-title":"Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients","volume":"26","author":"Ding Q","year":"2017","unstructured":"Ding Q, Chen J, Fan J, Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients. Eur Spine J. 2017;26(11):2969\u20132977.10.1007\/s00586-017-5286-128865035"},{"issue":"1","key":"r33","series-title":"Arch Osteoporos","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11657-019-0628-8","article-title":"Bone union after spinal fusion surgery using local bone in long-term bisphosphonate users: a prospective comparative study","volume":"14","author":"Kang T","year":"2019","unstructured":"Kang T, Park SY, Hong SH, Bone union after spinal fusion surgery using local bone in long-term bisphosphonate users: a prospective comparative study. Arch Osteoporos. 2019;14(1):74.3125630410.1007\/s11657-019-0628-8"},{"issue":"23","key":"r34","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"E1464","DOI":"10.1097\/BRS.0b013e31826ca2a8","article-title":"Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study","volume":"37","author":"Ohtori S","year":"2012","unstructured":"Ohtori S, Inoue G, Orita S, Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37(23):E1464\u2013E1468.10.1097\/BRS.0b013e31826ca2a8"},{"issue":"1","key":"r35","series-title":"J Cell Biochem","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes C","year":"2016","unstructured":"Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and benefits of bisphosphonate therapies. J Cell Biochem. 2016;117(1):20\u201328.2609668710.1002\/jcb.25266"},{"issue":"2","key":"r36","series-title":"Int J Clin Pract","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han SL","year":"2012","unstructured":"Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012;66(2):199\u2013209.10.1111\/j.1742-1241.2011.02837.x"},{"issue":"5","key":"r37","series-title":"J Bone Joint Surg Am","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2106\/JBJS.16.00230","article-title":"Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study","volume":"99","author":"Ebata S","year":"2017","unstructured":"Ebata S, Takahashi J, Hasegawa T, Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg Am. 2017;99(5):365\u2013372.10.2106\/JBJS.16.00230"},{"issue":"3","key":"r38","series-title":"Eur Spine J","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00586-015-4342-y","article-title":"An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data","volume":"26","author":"Cho PG","year":"2017","unstructured":"Cho PG, Ji GY, Shin DA, An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J. 2017;26(3):691\u2013697.10.1007\/s00586-015-4342-y26661639"},{"issue":"4","key":"r39","series-title":"J Korean Neurosurg Soc","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3340\/jkns.2017.0216","article-title":"The effect of postoperative use of teriparatide reducing screw loosening in osteoporotic patients","volume":"61","author":"Kim JW","year":"2018","unstructured":"Kim JW, Park SW, Kim YB, Ko MJ. The effect of postoperative use of teriparatide reducing screw loosening in osteoporotic patients. J Korean Neurosurg Soc. 2018;61(4):494\u2013502.10.3340\/jkns.2017.021629724093"},{"issue":"2","key":"r40","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.spinee.2014.08.001","article-title":"Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis","volume":"15","author":"Sugiura T","year":"2015","unstructured":"Sugiura T, Kashii M, Matsuo Y, Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis. Spine J. 2015;15(2):298\u2013306.10.1016\/j.spinee.2014.08.00125110274"},{"issue":"4","key":"r41","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.spinee.2005.10.010","article-title":"Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model","volume":"6","author":"Lawrence JP","year":"2006","unstructured":"Lawrence JP, Ennis F, White AP, Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model. Spine J. 2006;6(4):385\u2013390.10.1016\/j.spinee.2005.10.010"},{"issue":"10","key":"r42","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00198-013-2385-7","article-title":"Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model","volume":"24","author":"Qiu Z","year":"2013","unstructured":"Qiu Z, Wei L, Liu J, Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model. Osteoporos Int. 2013;24(10):2693\u20132700.10.1007\/s00198-013-2385-7"},{"issue":"2","key":"r43","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/BRS.0b013e318191e687","article-title":"Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model","volume":"34","author":"O\u2019Loughlin PF","year":"2009","unstructured":"O\u2019Loughlin PF, Cunningham ME, Bukata SV, Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine (Phila Pa 1976). 2009;34(2):121\u2013130.10.1097\/BRS.0b013e318191e687"},{"issue":"2","key":"r44","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/BRS.0b013e3181b71a96","article-title":"Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model","volume":"35","author":"Lehman RA Jr","year":"2010","unstructured":"Lehman RA Jr, Dmitriev AE, Cardoso MJ, Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model. Spine (Phila Pa 1976). 2010;35(2):146\u2013152.10.1097\/BRS.0b013e3181b71a96"},{"issue":"3","key":"r45","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black DM","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254\u2013262.2678987310.1056\/NEJMcp1513724"},{"issue":"2","key":"r46","series-title":"Calcif Tissue Int","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis","volume":"89","author":"Rizzoli R","year":"2011","unstructured":"Rizzoli R, Reginster JY, Boonen S, Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011;89(2):91\u2013104.10.1007\/s00223-011-9499-821637997"},{"issue":"16)(suppl 1","key":"r47","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/00007632-200208151-00007","article-title":"Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute","volume":"27","author":"Boden SD","year":"2002","unstructured":"Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002;27(16)(suppl 1):S26\u2013S31.10.1097\/00007632-200208151-00007"},{"issue":"6","key":"r48","series-title":"Cytokine Growth Factor Rev","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre S","year":"2004","unstructured":"Theoleyre S, Wittrant Y, Tat SK, The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15(6):457\u2013475.1556160210.1016\/j.cytogfr.2004.06.004"},{"key":"r49","series-title":"Curr Top Dev Biol","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0070-2153(06)76004-5","article-title":"Wnt signaling: a key regulator of bone mass","volume":"76","author":"Baron R","year":"2006","unstructured":"Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol. 2006;76:103\u2013127.10.1016\/S0070-2153(06)76004-517118265"},{"issue":"9","key":"r50","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u20131045.1877520410.4065\/83.9.1032"},{"issue":"12","key":"r51","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan GA","year":"1996","unstructured":"Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692\u20132696.10.1172\/JCI1187228675678"},{"issue":"5","key":"r52","series-title":"Pharmacol Rep","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.pharep.2018.03.011","article-title":"Bisphosphonates: future perspective for neurological disorders","volume":"70","author":"Zameer S","year":"2018","unstructured":"Zameer S, Najmi AK, Vohora D, Akhtar M. Bisphosphonates: future perspective for neurological disorders. Pharmacol Rep. 2018;70(5):900\u2013907.10.1016\/j.pharep.2018.03.011"},{"issue":"3","key":"r53","series-title":"Expert Opin Drug Discov","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1517\/17460441.2016.1143814","article-title":"Approaches for designing new potent inhibitors of farnesyl pyrophosphate synthase","volume":"11","author":"Rodriguez JB","year":"2016","unstructured":"Rodriguez JB, Falcone BN, Szajnman SH. Approaches for designing new potent inhibitors of farnesyl pyrophosphate synthase. Expert Opin Drug Discov. 2016;11(3):307\u2013320.10.1517\/17460441.2016.114381426781029"},{"issue":"4","key":"r54","series-title":"Bone","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron R","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677\u2013692.2114599910.1016\/j.bone.2010.11.020"},{"issue":"10","key":"r55","series-title":"Horm Metab Res","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis","volume":"41","author":"Anastasilakis AD","year":"2009","unstructured":"Anastasilakis AD, Toulis KA, Goulis DG, Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009;41(10):721\u2013729.10.1055\/s-0029-122410919536731"},{"issue":"8","key":"r56","series-title":"J Endocr Soc","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas AV","year":"2018","unstructured":"Haas AV, LeBoff MS. Osteoanabolic agents for osteoporosis. J Endocr Soc. 2018;2(8):922\u2013932.10.1210\/js.2018-0011830087947"},{"issue":"1","key":"r57","series-title":"J Bone Miner Res","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi D","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19\u201326.2059341110.1002\/jbmr.173"},{"issue":"6","key":"r58","series-title":"J Bone Miner Res","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li X","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860\u2013869.1826931010.1359\/jbmr.080216"},{"issue":"2","key":"r59","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.spinee.2012.03.035","article-title":"The effect of therapies for osteoporosis on spine fusion: a systematic review","volume":"13","author":"Hirsch BP","year":"2013","unstructured":"Hirsch BP, Unnanuntana A, Cunningham ME, Lane JM. The effect of therapies for osteoporosis on spine fusion: a systematic review. Spine J. 2013;13(2):190\u2013199.10.1016\/j.spinee.2012.03.03522658879"},{"issue":"4","key":"r60","series-title":"Curr Osteoporos Rep","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11914-014-0237-9","article-title":"Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches","volume":"12","author":"Cosman F","year":"2014","unstructured":"Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep. 2014;12(4):385\u2013395.2534147610.1007\/s11914-014-0237-9"},{"issue":"6","key":"r61","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black DM","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555\u2013565.1609346410.1056\/NEJMoa050336"},{"issue":"8","key":"r62","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings SR","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u2013765.10.1056\/NEJMoa080949319671655"},{"issue":"7","key":"r63","series-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone HG","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u2013523.2854609710.1016\/S2213-8587(17)30138-9"},{"issue":"15","key":"r64","series-title":"Am J Health Syst Pharm","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2146\/ajhp100493","article-title":"Denosumab for treatment of postmenopausal osteoporosis","volume":"68","author":"Chitre M","year":"2011","unstructured":"Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68(15):1409\u20131418.2178503010.2146\/ajhp100493"},{"issue":"7","key":"r65","series-title":"Orthop Traumatol Surg Res","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.otsr.2018.07.015","article-title":"Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion","volume":"104","author":"Ide M","year":"2018","unstructured":"Ide M, Yamada K, Kaneko K, Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion. Orthop Traumatol Surg Res. 2018;104(7):1043\u20131048.10.1016\/j.otsr.2018.07.01530179720"},{"issue":"11","key":"r66","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","article-title":"Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab","volume":"21","author":"Toulis KA","year":"2010","unstructured":"Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int. 2010;21(11):1963\u20131964.10.1007\/s00198-009-1145-1"},{"issue":"3","key":"r67","series-title":"Br J Oral Maxillofac Surg","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor KH","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48(3):221\u2013223.10.1016\/j.bjoms.2009.08.03019836866"},{"issue":"35","key":"r68","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck AT","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20135139.2106003310.1200\/JCO.2010.29.7101"},{"key":"r69","series-title":"Bone","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky MS","year":"2017","unstructured":"Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63\u201375.10.1016\/j.bone.2016.10.01927789417"},{"issue":"16","key":"r70","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman F","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u20131543.2764114310.1056\/NEJMoa1607948"},{"issue":"1","key":"r71","series-title":"Osteoporos Sarcopenia","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","article-title":"Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials","volume":"6","author":"M\u00f6ckel L","year":"2020","unstructured":"M\u00f6ckel L, Bartneck M, M\u00f6ckel C. Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials. Osteoporos Sarcopenia. 2020;6(1):20\u201326.10.1016\/j.afos.2020.02.00332226829"},{"issue":"15","key":"r72","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag KG","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u20131427.10.1056\/NEJMoa1708322"},{"issue":"5-6","key":"r73","series-title":"Wien Med Wochenschr","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10354-019-00721-5","article-title":"Romosozumab: a novel bone anabolic treatment option for osteoporosis?","volume":"170","author":"Kerschan-Schindl K","year":"2020","unstructured":"Kerschan-Schindl K. Romosozumab: a novel bone anabolic treatment option for osteoporosis? Wien Med Wochenschr. 2020;170(5-6):124\u2013131.10.1007\/s10354-019-00721-531858345"},{"issue":"4","key":"r1","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00198-016-3865-3","article-title":"The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA","volume":"28","author":"Wright NC","year":"2017","unstructured":"Wright NC, Saag KG, Dawson-Hughes B, The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int. 2017;28(4):1225\u20131232.10.1007\/s00198-016-3865-327966104"},{"key":"r2","article-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","author":"Office of the Surgeon General","year":"2004","unstructured":"Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General; 2004."},{"issue":"9","key":"r3","series-title":"Geriatrics","first-page":"20","article-title":"Osteoporosis in older men: discovering when and how to treat it","volume":"54","author":"Siddiqui NA","year":"1999","unstructured":"Siddiqui NA, Shetty KR, Duthie EH Jr. Osteoporosis in older men: discovering when and how to treat it. Geriatrics. 1999;54(9):20\u201322, 27\u201328, 30 passim.10494225"},{"issue":"4","key":"r4","series-title":"Clin Spine Surg","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/BSD.0000000000000376","article-title":"Medical management of osteoporosis for elective spine surgery","volume":"29","author":"Hassanzadeh H","year":"2016","unstructured":"Hassanzadeh H, Puvanesarajah V, Dalkin AC. Medical management of osteoporosis for elective spine surgery. Clin Spine Surg. 2016;29(4):134\u2013140.10.1097\/BSD.000000000000037627100945"},{"issue":"7","key":"r5","series-title":"Am Fam Physician","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion JM","year":"2003","unstructured":"Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician. 2003;67(7):1521\u20131526.12722852"},{"issue":"43","key":"r6","series-title":"Medicine (Baltimore)","doi-asserted-by":"publisher","first-page":"e8294","DOI":"10.1097\/MD.0000000000008294","article-title":"Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: a cross-sectional study in Gansu province, Northwestern of China","volume":"96","author":"Tian L","year":"2017","unstructured":"Tian L, Yang R, Wei L, Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: a cross-sectional study in Gansu province, Northwestern of China. Medicine (Baltimore). 2017;96(43):e8294.10.1097\/MD.0000000000008294"},{"issue":"1","key":"r7","series-title":"Endocrinol Metab Clin North Am","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ecl.2013.09.004","article-title":"Osteoporosis-associated fracture and diabetes","volume":"43","author":"Kurra S","year":"2014","unstructured":"Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin North Am. 2014;43(1):233\u2013243.10.1016\/j.ecl.2013.09.00424582100"},{"issue":"19)(suppl","key":"r8","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1097\/01.brs.0000236893.65878.39","article-title":"Instrumentation-related complications of multilevel fusions for adult spinal deformity patients over age 65: surgical considerations and treatment options in patients with poor bone quality","volume":"31","author":"DeWald CJ","year":"2006","unstructured":"DeWald CJ, Stanley T. Instrumentation-related complications of multilevel fusions for adult spinal deformity patients over age 65: surgical considerations and treatment options in patients with poor bone quality. Spine (Phila Pa 1976). 2006;31(19)(suppl):S144\u2013S151.10.1097\/01.brs.0000236893.65878.39"},{"issue":"4","key":"r9","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3171\/2010.4.SPINE09764","article-title":"Evaluation of pullout strength and failure mechanism of posterior instrumentation in normal and osteopenic thoracic vertebrae","volume":"13","author":"Paxinos O","year":"2010","unstructured":"Paxinos O, Tsitsopoulos PP, Zindrick MR, Evaluation of pullout strength and failure mechanism of posterior instrumentation in normal and osteopenic thoracic vertebrae. J Neurosurg Spine. 2010;13(4):469\u2013476.2088714410.3171\/2010.4.SPINE09764"},{"issue":"9","key":"r10","series-title":"Bone Joint Res","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1302\/2046-3758.59.2000580","article-title":"Pull-out strength of cemented solid versus fenestrated pedicle screws in osteoporotic vertebrae","volume":"5","author":"Leichtle CI","year":"2016","unstructured":"Leichtle CI, Lorenz A, Rothstock S, Pull-out strength of cemented solid versus fenestrated pedicle screws in osteoporotic vertebrae. Bone Joint Res. 2016;5(9):419\u2013426.10.1302\/2046-3758.59.200058027678328"},{"issue":"15","key":"r11","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1097\/00007632-199311000-00016","article-title":"Stability of transpedicle screwing for the osteoporotic spine. An in vitro study of the mechanical stability","volume":"18","author":"Okuyama K","year":"1993","unstructured":"Okuyama K, Sato K, Abe E, Stability of transpedicle screwing for the osteoporotic spine. An in vitro study of the mechanical stability. Spine (Phila Pa 1976). 1993;18(15):2240\u20132245.10.1097\/00007632-199311000-00016"},{"issue":"21","key":"r12","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1097\/00007632-199411000-00008","article-title":"Effects of bone mineral density on pedicle screw fixation","volume":"19","author":"Halvorson TL","year":"1994","unstructured":"Halvorson TL, Kelley LA, Thomas KA, Effects of bone mineral density on pedicle screw fixation. Spine (Phila Pa 1976). 1994;19(21):2415\u20132420.10.1097\/00007632-199411000-00008"},{"issue":"11","key":"r13","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/00007632-199111000-00015","article-title":"An experimental study on transpedicular screw fixation in relation to osteoporosis of the lumbar spine","volume":"16","author":"Soshi S","year":"1991","unstructured":"Soshi S, Shiba R, Kondo H, Murota K. An experimental study on transpedicular screw fixation in relation to osteoporosis of the lumbar spine. Spine (Phila Pa 1976). 1991;16(11):1335\u20131341.10.1097\/00007632-199111000-00015"},{"issue":"6","key":"r14","series-title":"J Orthop Sci","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jos.2018.06.009","article-title":"Effect of osteoporosis on the clinical and radiological outcomes following one-level posterior lumbar interbody fusion","volume":"23","author":"Cho JH","year":"2018","unstructured":"Cho JH, Hwang CJ, Kim H, Effect of osteoporosis on the clinical and radiological outcomes following one-level posterior lumbar interbody fusion. J Orthop Sci. 2018;23(6):870\u2013877.10.1016\/j.jos.2018.06.00930431006"},{"issue":"17","key":"r15","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1097\/BRS.0b013e31824e4888","article-title":"Incidence, risk factors, and natural course of proximal junctional kyphosis: surgical outcomes review of adult idiopathic scoliosis. Minimum 5 years of follow-up","volume":"37","author":"Yagi M","year":"2012","unstructured":"Yagi M, King AB, Boachie-Adjei O. Incidence, risk factors, and natural course of proximal junctional kyphosis: surgical outcomes review of adult idiopathic scoliosis. Minimum 5 years of follow-up. Spine (Phila Pa 1976). 2012;37(17):1479\u20131489.10.1097\/BRS.0b013e31824e4888"},{"key":"r16","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.wneu.2016.11.135","article-title":"Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients","volume":"100","author":"Chaudhary N","year":"2017","unstructured":"Chaudhary N, Lee JS, Wu JY, Tharin S. Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients. World Neurosurg. 2017;100:551\u2013556.2792375810.1016\/j.wneu.2016.11.135"},{"issue":"8","key":"r17","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"E487","DOI":"10.1097\/BRS.0b013e31828826dd","article-title":"Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective","volume":"38","author":"Ohtori S","year":"2013","unstructured":"Ohtori S, Inoue G, Orita S, Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38(8):E487\u2013E492.10.1097\/BRS.0b013e31828826dd"},{"issue":"3","key":"r18","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3171\/2014.5.SPINE13656","article-title":"Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis","volume":"21","author":"Inoue G","year":"2014","unstructured":"Inoue G, Ueno M, Nakazawa T, Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine. 2014;21(3):425\u2013431.10.3171\/2014.5.SPINE1365624905394"},{"issue":"4","key":"r19","series-title":"Asian Spine J","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4184\/asj.2015.9.4.573","article-title":"More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery","volume":"9","author":"Ohtori S","year":"2015","unstructured":"Ohtori S, Orita S, Yamauchi K, More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. Asian Spine J. 2015;9(4):573\u2013580.2624071710.4184\/asj.2015.9.4.573"},{"issue":"9886","key":"r20","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai JN","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H, Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50\u201356.10.1016\/S0140-6736(13)60856-9"},{"issue":"1","key":"r21","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.spinee.2015.08.061","article-title":"Effect of a selective estrogen receptor modulator on bone formation in osteoporotic spine fusion using an ovariectomized rat model","volume":"16","author":"Park SB","year":"2016","unstructured":"Park SB, Kim CH, Hong M, Effect of a selective estrogen receptor modulator on bone formation in osteoporotic spine fusion using an ovariectomized rat model. Spine J. 2016;16(1):72\u201381.10.1016\/j.spinee.2015.08.061"},{"issue":"9","key":"r22","series-title":"J Orthop Res","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/jor.22763","article-title":"Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis","volume":"33","author":"Yasen M","year":"2015","unstructured":"Yasen M, Li X, Jiang L, Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis. J Orthop Res. 2015;33(9):1297\u20131304.10.1002\/jor.22763"},{"issue":"18","key":"r23","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1097\/BRS.0b013e3181f49c47","article-title":"The influence of alendronate on spine fusion in an osteoporotic animal model","volume":"36","author":"Nakao S","year":"2011","unstructured":"Nakao S, Minamide A, Kawakami M, The influence of alendronate on spine fusion in an osteoporotic animal model. Spine (Phila Pa 1976). 2011;36(18):1446\u20131452.10.1097\/BRS.0b013e3181f49c47"},{"issue":"3","key":"r24","series-title":"J Orthop Res","first-page":"937","article-title":"Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia","volume":"36","author":"Yishake M","year":"2018","unstructured":"Yishake M, Yasen M, Jiang L, Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia. J Orthop Res. 2018;36(3):937\u2013944."},{"issue":"4","key":"r25","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3171\/2010.11.SPINE10245","article-title":"Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial","volume":"14","author":"Nagahama K","year":"2011","unstructured":"Nagahama K, Kanayama M, Togawa D, Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. J Neurosurg Spine. 2011;14(4):500\u2013507.2127554910.3171\/2010.11.SPINE10245"},{"issue":"4","key":"r26","series-title":"Clin Orthop Surg","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4055\/cios.2013.5.4.292","article-title":"The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion","volume":"5","author":"Park YS","year":"2013","unstructured":"Park YS, Kim HS, Baek SW, The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. Clin Orthop Surg. 2013;5(4):292\u2013297.10.4055\/cios.2013.5.4.29224340149"},{"issue":"1","key":"r27","series-title":"J Surg Res","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jss.2014.05.034","article-title":"Zoledronic acid infusion for lumbar interbody fusion in osteoporosis","volume":"192","author":"Tu CW","year":"2014","unstructured":"Tu CW, Huang KF, Hsu HT, Zoledronic acid infusion for lumbar interbody fusion in osteoporosis. J Surg Res. 2014;192(1):112\u2013116.2494854510.1016\/j.jss.2014.05.034"},{"issue":"4","key":"r28","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00198-015-3398-1","article-title":"Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion","volume":"27","author":"Chen F","year":"2016","unstructured":"Chen F, Dai Z, Kang Y, Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion. Osteoporos Int. 2016;27(4):1469\u20131476.10.1007\/s00198-015-3398-1"},{"issue":"8","key":"r29","series-title":"Eur Spine J","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00586-017-4959-0","article-title":"Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis","volume":"26","author":"Seki S","year":"2017","unstructured":"Seki S, Hirano N, Kawaguchi Y, Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J. 2017;26(8):2121\u20132127.10.1007\/s00586-017-4959-028116510"},{"issue":"1","key":"r30","series-title":"BMC Musculoskelet Disord","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12891-020-03452-6","article-title":"Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study","volume":"21","author":"Kawabata A","year":"2020","unstructured":"Kawabata A, Yoshii T, Hirai T, Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study. BMC Musculoskelet Disord. 2020;21(1):420.10.1186\/s12891-020-03452-632611386"},{"issue":"13","key":"r31","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/BRS.0000000000003426","article-title":"Weekly teriparatide versus bisphosphonate for bone union during 6 months after multi-level lumbar interbody fusion for osteoporotic patients: a multicenter, prospective, randomized study","volume":"45","author":"Oba H","year":"2020","unstructured":"Oba H, Takahashi J, Yokomichi H, Weekly teriparatide versus bisphosphonate for bone union during 6 months after multi-level lumbar interbody fusion for osteoporotic patients: a multicenter, prospective, randomized study. Spine (Phila Pa 1976). 2020;45(13):863\u2013871.10.1097\/BRS.0000000000003426"},{"issue":"11","key":"r32","series-title":"Eur Spine J","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s00586-017-5286-1","article-title":"Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients","volume":"26","author":"Ding Q","year":"2017","unstructured":"Ding Q, Chen J, Fan J, Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients. Eur Spine J. 2017;26(11):2969\u20132977.10.1007\/s00586-017-5286-128865035"},{"issue":"1","key":"r33","series-title":"Arch Osteoporos","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11657-019-0628-8","article-title":"Bone union after spinal fusion surgery using local bone in long-term bisphosphonate users: a prospective comparative study","volume":"14","author":"Kang T","year":"2019","unstructured":"Kang T, Park SY, Hong SH, Bone union after spinal fusion surgery using local bone in long-term bisphosphonate users: a prospective comparative study. Arch Osteoporos. 2019;14(1):74.3125630410.1007\/s11657-019-0628-8"},{"issue":"23","key":"r34","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"E1464","DOI":"10.1097\/BRS.0b013e31826ca2a8","article-title":"Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study","volume":"37","author":"Ohtori S","year":"2012","unstructured":"Ohtori S, Inoue G, Orita S, Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37(23):E1464\u2013E1468.10.1097\/BRS.0b013e31826ca2a8"},{"issue":"1","key":"r35","series-title":"J Cell Biochem","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes C","year":"2016","unstructured":"Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and benefits of bisphosphonate therapies. J Cell Biochem. 2016;117(1):20\u201328.2609668710.1002\/jcb.25266"},{"issue":"2","key":"r36","series-title":"Int J Clin Pract","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han SL","year":"2012","unstructured":"Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012;66(2):199\u2013209.10.1111\/j.1742-1241.2011.02837.x"},{"issue":"5","key":"r37","series-title":"J Bone Joint Surg Am","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2106\/JBJS.16.00230","article-title":"Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study","volume":"99","author":"Ebata S","year":"2017","unstructured":"Ebata S, Takahashi J, Hasegawa T, Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg Am. 2017;99(5):365\u2013372.10.2106\/JBJS.16.00230"},{"issue":"3","key":"r38","series-title":"Eur Spine J","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00586-015-4342-y","article-title":"An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data","volume":"26","author":"Cho PG","year":"2017","unstructured":"Cho PG, Ji GY, Shin DA, An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J. 2017;26(3):691\u2013697.10.1007\/s00586-015-4342-y26661639"},{"issue":"4","key":"r39","series-title":"J Korean Neurosurg Soc","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3340\/jkns.2017.0216","article-title":"The effect of postoperative use of teriparatide reducing screw loosening in osteoporotic patients","volume":"61","author":"Kim JW","year":"2018","unstructured":"Kim JW, Park SW, Kim YB, Ko MJ. The effect of postoperative use of teriparatide reducing screw loosening in osteoporotic patients. J Korean Neurosurg Soc. 2018;61(4):494\u2013502.10.3340\/jkns.2017.021629724093"},{"issue":"2","key":"r40","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.spinee.2014.08.001","article-title":"Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis","volume":"15","author":"Sugiura T","year":"2015","unstructured":"Sugiura T, Kashii M, Matsuo Y, Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis. Spine J. 2015;15(2):298\u2013306.10.1016\/j.spinee.2014.08.00125110274"},{"issue":"4","key":"r41","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.spinee.2005.10.010","article-title":"Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model","volume":"6","author":"Lawrence JP","year":"2006","unstructured":"Lawrence JP, Ennis F, White AP, Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model. Spine J. 2006;6(4):385\u2013390.10.1016\/j.spinee.2005.10.010"},{"issue":"10","key":"r42","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00198-013-2385-7","article-title":"Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model","volume":"24","author":"Qiu Z","year":"2013","unstructured":"Qiu Z, Wei L, Liu J, Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model. Osteoporos Int. 2013;24(10):2693\u20132700.10.1007\/s00198-013-2385-7"},{"issue":"2","key":"r43","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/BRS.0b013e318191e687","article-title":"Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model","volume":"34","author":"O\u2019Loughlin PF","year":"2009","unstructured":"O\u2019Loughlin PF, Cunningham ME, Bukata SV, Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine (Phila Pa 1976). 2009;34(2):121\u2013130.10.1097\/BRS.0b013e318191e687"},{"issue":"2","key":"r44","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/BRS.0b013e3181b71a96","article-title":"Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model","volume":"35","author":"Lehman RA Jr","year":"2010","unstructured":"Lehman RA Jr, Dmitriev AE, Cardoso MJ, Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model. Spine (Phila Pa 1976). 2010;35(2):146\u2013152.10.1097\/BRS.0b013e3181b71a96"},{"issue":"3","key":"r45","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black DM","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254\u2013262.2678987310.1056\/NEJMcp1513724"},{"issue":"2","key":"r46","series-title":"Calcif Tissue Int","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis","volume":"89","author":"Rizzoli R","year":"2011","unstructured":"Rizzoli R, Reginster JY, Boonen S, Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011;89(2):91\u2013104.10.1007\/s00223-011-9499-821637997"},{"issue":"16)(suppl 1","key":"r47","series-title":"Spine (Phila Pa 1976)","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/00007632-200208151-00007","article-title":"Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute","volume":"27","author":"Boden SD","year":"2002","unstructured":"Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002;27(16)(suppl 1):S26\u2013S31.10.1097\/00007632-200208151-00007"},{"issue":"6","key":"r48","series-title":"Cytokine Growth Factor Rev","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre S","year":"2004","unstructured":"Theoleyre S, Wittrant Y, Tat SK, The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15(6):457\u2013475.1556160210.1016\/j.cytogfr.2004.06.004"},{"key":"r49","series-title":"Curr Top Dev Biol","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0070-2153(06)76004-5","article-title":"Wnt signaling: a key regulator of bone mass","volume":"76","author":"Baron R","year":"2006","unstructured":"Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol. 2006;76:103\u2013127.10.1016\/S0070-2153(06)76004-517118265"},{"issue":"9","key":"r50","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u20131045.1877520410.4065\/83.9.1032"},{"issue":"12","key":"r51","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan GA","year":"1996","unstructured":"Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692\u20132696.10.1172\/JCI1187228675678"},{"issue":"5","key":"r52","series-title":"Pharmacol Rep","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.pharep.2018.03.011","article-title":"Bisphosphonates: future perspective for neurological disorders","volume":"70","author":"Zameer S","year":"2018","unstructured":"Zameer S, Najmi AK, Vohora D, Akhtar M. Bisphosphonates: future perspective for neurological disorders. Pharmacol Rep. 2018;70(5):900\u2013907.10.1016\/j.pharep.2018.03.011"},{"issue":"3","key":"r53","series-title":"Expert Opin Drug Discov","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1517\/17460441.2016.1143814","article-title":"Approaches for designing new potent inhibitors of farnesyl pyrophosphate synthase","volume":"11","author":"Rodriguez JB","year":"2016","unstructured":"Rodriguez JB, Falcone BN, Szajnman SH. Approaches for designing new potent inhibitors of farnesyl pyrophosphate synthase. Expert Opin Drug Discov. 2016;11(3):307\u2013320.10.1517\/17460441.2016.114381426781029"},{"issue":"4","key":"r54","series-title":"Bone","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron R","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677\u2013692.2114599910.1016\/j.bone.2010.11.020"},{"issue":"10","key":"r55","series-title":"Horm Metab Res","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis","volume":"41","author":"Anastasilakis AD","year":"2009","unstructured":"Anastasilakis AD, Toulis KA, Goulis DG, Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009;41(10):721\u2013729.10.1055\/s-0029-122410919536731"},{"issue":"8","key":"r56","series-title":"J Endocr Soc","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas AV","year":"2018","unstructured":"Haas AV, LeBoff MS. Osteoanabolic agents for osteoporosis. J Endocr Soc. 2018;2(8):922\u2013932.10.1210\/js.2018-0011830087947"},{"issue":"1","key":"r57","series-title":"J Bone Miner Res","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi D","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19\u201326.2059341110.1002\/jbmr.173"},{"issue":"6","key":"r58","series-title":"J Bone Miner Res","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li X","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860\u2013869.1826931010.1359\/jbmr.080216"},{"issue":"2","key":"r59","series-title":"Spine J","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.spinee.2012.03.035","article-title":"The effect of therapies for osteoporosis on spine fusion: a systematic review","volume":"13","author":"Hirsch BP","year":"2013","unstructured":"Hirsch BP, Unnanuntana A, Cunningham ME, Lane JM. The effect of therapies for osteoporosis on spine fusion: a systematic review. Spine J. 2013;13(2):190\u2013199.10.1016\/j.spinee.2012.03.03522658879"},{"issue":"4","key":"r60","series-title":"Curr Osteoporos Rep","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11914-014-0237-9","article-title":"Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches","volume":"12","author":"Cosman F","year":"2014","unstructured":"Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep. 2014;12(4):385\u2013395.2534147610.1007\/s11914-014-0237-9"},{"issue":"6","key":"r61","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black DM","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555\u2013565.1609346410.1056\/NEJMoa050336"},{"issue":"8","key":"r62","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings SR","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u2013765.10.1056\/NEJMoa080949319671655"},{"issue":"7","key":"r63","series-title":"Lancet Diabetes Endocrinol","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone HG","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u2013523.2854609710.1016\/S2213-8587(17)30138-9"},{"issue":"15","key":"r64","series-title":"Am J Health Syst Pharm","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2146\/ajhp100493","article-title":"Denosumab for treatment of postmenopausal osteoporosis","volume":"68","author":"Chitre M","year":"2011","unstructured":"Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68(15):1409\u20131418.2178503010.2146\/ajhp100493"},{"issue":"7","key":"r65","series-title":"Orthop Traumatol Surg Res","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.otsr.2018.07.015","article-title":"Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion","volume":"104","author":"Ide M","year":"2018","unstructured":"Ide M, Yamada K, Kaneko K, Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion. Orthop Traumatol Surg Res. 2018;104(7):1043\u20131048.10.1016\/j.otsr.2018.07.01530179720"},{"issue":"11","key":"r66","series-title":"Osteoporos Int","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","article-title":"Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab","volume":"21","author":"Toulis KA","year":"2010","unstructured":"Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int. 2010;21(11):1963\u20131964.10.1007\/s00198-009-1145-1"},{"issue":"3","key":"r67","series-title":"Br J Oral Maxillofac Surg","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor KH","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48(3):221\u2013223.10.1016\/j.bjoms.2009.08.03019836866"},{"issue":"35","key":"r68","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck AT","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20135139.2106003310.1200\/JCO.2010.29.7101"},{"key":"r69","series-title":"Bone","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky MS","year":"2017","unstructured":"Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63\u201375.10.1016\/j.bone.2016.10.01927789417"},{"issue":"16","key":"r70","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman F","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u20131543.2764114310.1056\/NEJMoa1607948"},{"issue":"1","key":"r71","series-title":"Osteoporos Sarcopenia","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","article-title":"Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials","volume":"6","author":"M\u00f6ckel L","year":"2020","unstructured":"M\u00f6ckel L, Bartneck M, M\u00f6ckel C. Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials. Osteoporos Sarcopenia. 2020;6(1):20\u201326.10.1016\/j.afos.2020.02.00332226829"},{"issue":"15","key":"r72","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag KG","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u20131427.10.1056\/NEJMoa1708322"},{"issue":"5-6","key":"r73","series-title":"Wien Med Wochenschr","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10354-019-00721-5","article-title":"Romosozumab: a novel bone anabolic treatment option for osteoporosis?","volume":"170","author":"Kerschan-Schindl K","year":"2020","unstructured":"Kerschan-Schindl K. Romosozumab: a novel bone anabolic treatment option for osteoporosis? Wien Med Wochenschr. 2020;170(5-6):124\u2013131.10.1007\/s10354-019-00721-531858345"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/50\/6\/article-pE13.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/50\/6\/article-pE13.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/50\/6\/article-pE13.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:20:26Z","timestamp":1779524426000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/50\/6\/article-pE13.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":146,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2021.3.focus201049","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}